Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-24T09:07:33.586Z Has data issue: false hasContentIssue false

11 - The Role of Antidepressants in Managing Bipolar II Disorder

from Section 1 - Domain Chapters

Published online by Cambridge University Press:  17 December 2018

By
Joseph F. Goldberg
Edited by
Gordon Parker
Gordon Parker
Affiliation:
University of New South Wales, Sydney
Get access
Type
Chapter
Information
Bipolar II Disorder
Modelling, Measuring and Managing
 , pp. 113 - 128
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altshuler, L.L, Sugar, C.A., McElroy, S.L., et al. (2017) Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. American Journal of Psychiatry, 174, 266–76.CrossRefGoogle ScholarPubMed
Altshuler, L.L., Post, R.M., Hellemann, G., et al. (2009). Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. Journal of Clinical Psychiatry, 70, 450–7.Google ScholarPubMed
Altshuler, L.L., Suppes, T., Black, D., et al. (2003). Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at one-year follow-up. American Journal of Psychiatry, 160, 1252–62.Google Scholar
Amsterdam, J.D. and Shults, J. (2010a) Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomised, double-blind, placebo substitution study. American Journal of Psychiatry, 167, 792–800.CrossRefGoogle ScholarPubMed
Amsterdam, J.D. and Shults, J. (2010b). Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. Journal of Clinical Psychopharmacology, 30, 306–11.CrossRefGoogle ScholarPubMed
Amsterdam, J.D., Brunswick, D.J. (2003). Antidepressant monotherapy for Bipolar Type II major depression. Journal of Affective Disorders, 5, 388–95.Google ScholarPubMed
Amsterdam, J.D., Lorenzo-Luaces, L., DeRubeis, R.J. (2016b). Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression. Bipolar Disorders, 18, 563–70.CrossRefGoogle ScholarPubMed
Amsterdam, J.D., Lorenzo-Luaces, L., Soeller, I., et al. (2016a). Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. British Journal of Psychiatry, 208, 359–65.Google Scholar
Amsterdam, J.D., Luo, L., Shults, J. (2013). Efficacy and mood conversion rate during long term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. British Journal of Psychiatry, 202, 301–6.CrossRefGoogle ScholarPubMed
Amsterdam, J.D., Shults, J. (2005a). Fluoxetine monotherapy for Bipolar II and Bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology, 20, 257–64.Google Scholar
Amsterdam, J.D., Shults, J. (2005b). Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of Bipolar Type I and Type II major depression – lack of manic induction. Journal of Affective Disorders, 87, 121–30.Google Scholar
Amsterdam, J.D., Shults, J., Brunswick, D.J. and Hundert, M. (2004). Short-term fluoxetine monotherapy for Bipolar Type II or Bipolar NOS major depression – low manic switch rate. Bipolar Disorders, 6, 75–81.Google Scholar
Bauer, M.S., Wisniewski, S.R., Marangell, L.B., et al. for the STEP-BD Investigators (2006). Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Journal of Clinical Psychiatry, 67, 48–55.CrossRefGoogle ScholarPubMed
Bond, D.J., Noronha, M.M., Kauer-Sant'Anna, M., Lam, R.W. and Yatham, L.N. (2008). Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 69, 1589–601.Google ScholarPubMed
Calabrese, J.R., Ketter, T.A., Youakim, J.M., Tiller, J.M., Yang, R. and Frye, M.A. (2010) Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. Journal of Clinical Psychiatry, 71, 1363–70.Google ScholarPubMed
Daray, F.M., Thommi, S.B. and Ghaemi, S.N. (2010). The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disorders, 12, 702–6.CrossRefGoogle Scholar
Diazgranados, N., Ibrahim, L., Brutsche, N.E., et al. (2010). A randomized add-on trial of an N methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry, 67, 793–802.CrossRefGoogle Scholar
Fava, M., Rush, A.J., Alpert, J.E., et al. (2008). Differences in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry, 165, 342–51.CrossRefGoogle ScholarPubMed
Frye, M.A., Grunze, H., Suppes, T. et al. (2007). A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. American Journal of Psychiatry, 164, 1242–9.Google Scholar
Frye, M.A., Helleman, G., McElroy, S.L., et al. (2009). Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. American Journal of Psychiatry, 166, 164–72.Google Scholar
Ghaemi, S.N., Ostacher, M.M., El-Mallakh, R.S., et al. (2010). Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. Journal of Clinical Psychiatry, 71, 372–80.Google ScholarPubMed
Ghaemi, S.N., Rosenquist, K.J., Ko, J.Y., et al. (2004). Antidepressant treatment in bipolar versus unipolar depression. American Journal of Psychiatry, 161, 163–5.CrossRefGoogle ScholarPubMed
Goldberg, J.F. and Truman, C.J. (2003). Antidepressant-induced mania: an overview of current controversies. Bipolar Disorders, 5, 407–20.Google Scholar
Goldberg, J.F. and Whiteside, J.E. (2002). The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. Journal of Clinical Psychiatry, 63, 791–5.Google Scholar
Goldberg, J.F., Burdick, K.E., Endick, C.J. (2004). Preliminary randomized, double-blind, placebo-controlled trial of pramipexole for treatment-resistant bipolar depression. American Journal of Psychiatry, 161, 564–6.CrossRefGoogle ScholarPubMed
Goldberg, J.F., Garno, J.L., Callahan, A.M., et al. (2008). Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. Journal of Clinical Psychiatry, 69, 1751–7.Google ScholarPubMed
Goldberg, J.F., Perlis, R.H., Bowden, C.L., et al. (2009). Mania symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. American Journal of Psychiatry, 166, 173–81.CrossRefGoogle Scholar
Goldberg, J.F., Perlis, R.H., Ghaemi, S.N., et al. (2007) Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. American Journal of Psychiatry, 164, 1348–55.CrossRefGoogle ScholarPubMed
Himmelhoch, J.M., Thase, M.E., Mallinger, A.G. and Houck, P. (1991). Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry, 148, 910–6.Google ScholarPubMed
Ionescu, D.F., Luckenbaugh, D.A., Niciu, M.J., et al. (2015). A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders, 17, 438–43.Google Scholar
Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.Google Scholar
Kelly, T.F. and Lieberman, D.Z. (2014). The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. Journal of Affective Disorders, 167, 333–5.CrossRefGoogle ScholarPubMed
Leon, A.C., Fiedorowicz, J.G., Solomon, D.A., et al. (2015). Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders. Journal of Clinical Psychiatry, 75, 720–7.Google Scholar
Leverich, G.S., Altshuler, L.L., Frye, M.A., et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilisers. American Journal of Psychiatry, 163, 232–9.Google Scholar
MacQueen, G.M., Young, L.T., Marriott, M., et al. (2002). Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatrica Scandinavica, 105, 414–18.CrossRefGoogle ScholarPubMed
Manwani, S.G., Pardo, T.B., Albanese, M.J., et al. (2006). Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. Journal of Clinical Psychiatry, 67, 1341–5.Google Scholar
Mathew, S.J., Gueorguieva, R., Brandt, C., et al. (2017). A randomized, double-blind, placebo controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder. Neuropsychopharmacology, doi:10.1038/npp.2017.106. [Epub ahead of print].Google Scholar
Mathew, S.J., Murrough, J.W., aan het Rot, M., et al. (2010). Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized placebo-controlled continuation trial. International Journal of Neuropsychopharmacology, 13, 71–82.Google Scholar
McElroy, S.L., Martens, B.E., Mori, N., et al. (2015). Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. International Clinical Psychopharmacology, 30, 6–13.CrossRefGoogle ScholarPubMed
McElroy, S.L., Weisler, R.H., Chang, W., et al. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry, 71, 163–74.Google ScholarPubMed
Möller, H.J., Bottlender, R., Grunze, H., Strauss, A. and Wittmann, J. (2001). Are antidepressants less effective in the acute treatment of Bipolar I compared to unipolar depression? Journal of Affective Disorders, 67, 141–6.CrossRefGoogle ScholarPubMed
Nemeroff, C.B., Evans, D.L., Gyulai, L., et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–12.Google Scholar
Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170, 1249–62.Google Scholar
Parker, G. and Brotchie, H. (2010). Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatrica Scandinavica, 121, 308–14.Google Scholar
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.Google Scholar
Peet, M. (1994). Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 164, 549–50.Google Scholar
Post, R.M., Altshuler, L.L., Leverich, G.S. et al. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 189, 124–31.CrossRefGoogle ScholarPubMed
Prien, R.F., Himmelhoch, J.M. and Kupfer, D.J. (1988). Treatment of mixed mania. Journal of Affective Disorders, 15, 9–15.Google Scholar
Rihmer, Z. and Pestality, P. (1999). Bipolar II disorder and suicidal behavior. Psychiatric Clinics of North America, 22, 667–73.Google Scholar
Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356, 1711–22.Google Scholar
Schneck, C.D., Miklowitz, D.J., Miyahara, S., et al. (2008). The prospective course of rapid cycling bipolar disorder: findings from the STEP-BD. American Journal of Psychiatry, 165, 370–7.Google Scholar
Schumann, G., Binder, E.B., Holte, A., et al. (2013). Stratified medicine for mental disorders. European Neuropsychopharmacology, 24, 5–50.CrossRefGoogle ScholarPubMed
Sidor, M.M. and MacQueen, G.M. (2011). Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 72, 156–67.Google ScholarPubMed
Soczynska, J.K., Kennedy, S.H., Alsuwaidan, M., et al. (2017). A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disorders, 19, 198–213.Google Scholar
Stoll, A.L., Mayer, P.V., Kolbrener, M., et al. (1994). Antidepressant-associated mania: a controlled comparison with spontaneous mania. American Journal of Psychiatry, 151, 1642–5.Google Scholar
Tohen, M., Frank, E., Bowden, C.L., et al. (2009). The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 11, 453–73.Google Scholar
Tondo, L., Vazquez, G. and Baldessarini, R.J. (2010). Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatrica Scandinavica, 121, 404–14.Google Scholar
Truman, C.J., Goldberg, J.F., Ghaemi, S.N., et al. (2007). Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Journal of Clinical Psychiatry, 68, 1472–9.Google Scholar
Vieta, E., Martinez-Aran, A, Goikolea, J.M. et al. (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry, 63, 508–12.Google ScholarPubMed
Vinberg, M., Mikkelsen, R.L., Kirkegaard, T., et al. (2017). Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder: a naturalistic study. Journal of Affective Disorders, 208, 521–7.Google Scholar
Vöhringer, P.A., Ostacher, M.J., El-Mallakh, R.S., et al. (2015). Antidepressants in type II versus type I bipolar depression: a randomized discontinuation trial. Journal of Clinical Psychopharmacology, 35, 605–8.Google Scholar
Young, L.T., Joffe, R.T., Robb, J.C. et al. (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American Journal of Psychiatry, 157, 124–6.Google Scholar
Zarate, C.A. Jr., Brutsche, N.E., Ibrahim, L., et al. (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry, 71, 939–46.CrossRefGoogle ScholarPubMed
Zarate, C.A. Jr., Payne, J.L., Singh, J. et al. (2004). Pramipexole for Bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.Google Scholar
Zarate, C.A. Jr., Quiroz, J.A., Singh, J.B., et al. (2005). An open-label trial of the glutamate modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry, 57, 430–2.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×